Insulet (Nasdaq:PODD) had to clear a series of hurdles to bring the Omnipod 5 automated insulin delivery system to those who need it. Speaking at DeviceTalks West in Santa Clara, California on Oct. 18, Mark Field, Insulet’s CTO, explained the trials and tribulations. He presented in a session titled “Overcoming Challenges to Develop the Omnipod […]
Special Content
Intuitive leaders weigh in on GLP-1 drugs and surgical robotics procedures
Intuitive Surgical executives say they see benefits to their business from GLP-1 weight loss drugs, even if investors aren’t quite so sure. Intuitive’s stock slid in after-hours trading today after the company posted Q3 results that exceeded analysts’ expectations on profits but fell short on sales. Even if they had beat The Street on both […]
How automated insulin delivery integration drives Dexcom CGM forward
Dexcom (Nasdaq:DXCM) is a company known as one of the market leaders in continuous glucose monitoring (CGM) technology. CGMs are a key system for people with diabetes to manage their condition. But, Dexcom has worked to ensure that its CGM technology goes beyond its standalone capabilities. The Dexcom G6, the company’s previous-generation CGM, integrates with a […]
New DeviceTalks series with MedtechWOMEN indicates a shift in medtech leadership
See more so you can be more in this new DeviceTalks web series. It’s 2007 and I’m lost in a sea of shoulder-to-shoulder blue and black suits, nearly lifting out of my seat to try and see the stage over row after row of people, all easily a foot taller than me. It was my […]
How Medtronic, Zimmer Biomet and Smith+Nephew approach medtech M&A
In a year with some massive acquisitions in medtech, there are still questions around an overall drop in M&A activity. According to Pete Cataldo, managing director and medtech head of Truist, deal volume in the sector fell 65% in the first half of 2023. However, despite high interest rates and a volatile stock market, there […]
State of the industry — Execs ‘more bullish than ever’ on medtech
Ernst & Young’s 2023 Pulse of the Industry medical technology report may not have been overly positive, but medtech executives certainly are. The EY report highlighted sluggish revenues and post-COVID-19 corrections leading to a growth decline. In fact, it was the lowest growth in medtech since 2015. Roughly half of medtech stock price gains realized […]
Boston Scientific targets M&A, AI to reach ‘next level’
Mike Mahoney uses fantasy football to describe Boston Scientific : He says that, if creating a medtech team, “it would be the draft you want.” Speaking at the company’s 2023 Investor Day event, the CEO set the theme as “next level.” He explained his aim to make Boston Scientific a “compelling” and “fantastic place to […]
Analysts: GLP-1 drugs should have minor impact on insulin pump market — but will boost CGMs
Based on conversations with diabetes experts, analysts are playing down the potentially negative impact of GLP-1 receptor agonists on the diabetes technology industry. The GLP-1 drug class, which includes Ozempic and Wegovy, has cast a shadow of doubt over diabetes technology of late. This therapeutic class, a glucagon-like peptide 1, has proven to lead to […]
5 keys to Mike Mahoney and Boston Scientific’s success
Boston Scientific’s market capitalization has grown nearly 10 times larger since Mike Mahoney joined as CEO in 2011. He shared key insights about corporate strategy at DeviceTalks Boston in May. Boston Scientific is one of the bright spots as the medical device industry goes through a rough patch. It’s more expensive to run a business, […]
How did medtech SPAC mergers fare?
Over the past few years, special purpose acquisition corporations (SPACs) have found their way into the medtech space. These businesses — built to bring private companies public — raise initial public offerings (IPOs). They then go and acquire existing companies, taking them public in the process. The value of these mergers varies, but some in […]
Stryker boosts guidance — but perhaps not enough — after Street-beating Q1
Stryker handily beat Wall Street expectations during its first quarter, though its guidance range increase may have disappointed investors. The morning after Stryker’s earnings announcement, SYK shares were down more than 1% to $294.12 apiece. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was up slightly. The orthopedic and surgical […]